Xuanzhu Biopharmaceutical gains HKEX green light for full circulation of 357.25 million H shares

Bulletin Express04-17 17:05

Hong Kong – Xuanzhu Biopharmaceutical Co., Ltd. announced that the Hong Kong Stock Exchange has approved the listing and dealing of 357.25 million H shares converted from unlisted shares under its H-share Full Circulation plan.

The conversion involves six participating shareholders, collectively holding 68.97% of the company’s issued share capital as of 17 April 2026. Key participants include Xuanzhu (HK) Biopharmaceutical (215.29 million shares, 41.57% post-conversion) and Sihuan Pharmaceutical Holdings Group (39.16 million shares, 7.56%). Upon completion, Xuanzhu’s entire issued share capital—517.95 million shares—will be tradable as H shares on the HKEX, eliminating the previous 68.97% block of unlisted shares.

The company will complete the required conversion and trading procedures and will update the market on further progress. Investors are advised to exercise caution when dealing in Xuanzhu Biopharmaceutical shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124608444?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 17:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124608444","market":"us","top_or_hot":-1,"title":"Xuanzhu Biopharmaceutical gains HKEX green light for full circulation of 357.25 million H shares","media":"Bulletin Express","content":"<p>Hong Kong – Xuanzhu Biopharmaceutical Co., Ltd. announced that the Hong Kong Stock Exchange has approved the listing and dealing of 357.25 million H shares converted from unlisted shares under its H-share Full Circulation plan.</p>\n<p>The conversion involves six participating shareholders, collectively holding 68.97% of the company’s issued share capital as of 17 April 2026. Key participants include Xuanzhu (HK) Biopharmaceutical (215.29 million shares, 41.57% post-conversion) and Sihuan Pharmaceutical Holdings Group (39.16 million shares, 7.56%). Upon completion, Xuanzhu’s entire issued share capital—517.95 million shares—will be tradable as H shares on the HKEX, eliminating the previous 68.97% block of unlisted shares.</p>\n<p>The company will complete the required conversion and trading procedures and will update the market on further progress. Investors are advised to exercise caution when dealing in Xuanzhu Biopharmaceutical shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xuanzhu Biopharmaceutical gains HKEX green light for full circulation of 357.25 million H shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanzhu Biopharmaceutical gains HKEX green light for full circulation of 357.25 million H shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-17 17:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong – Xuanzhu Biopharmaceutical Co., Ltd. announced that the Hong Kong Stock Exchange has approved the listing and dealing of 357.25 million H shares converted from unlisted shares under its H-share Full Circulation plan.</p>\n<p>The conversion involves six participating shareholders, collectively holding 68.97% of the company’s issued share capital as of 17 April 2026. Key participants include Xuanzhu (HK) Biopharmaceutical (215.29 million shares, 41.57% post-conversion) and Sihuan Pharmaceutical Holdings Group (39.16 million shares, 7.56%). Upon completion, Xuanzhu’s entire issued share capital—517.95 million shares—will be tradable as H shares on the HKEX, eliminating the previous 68.97% block of unlisted shares.</p>\n<p>The company will complete the required conversion and trading procedures and will update the market on further progress. Investors are advised to exercise caution when dealing in Xuanzhu Biopharmaceutical shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"轩竹生物-B","start_time":0,"source_url":"","article_id":"1124608444","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124608444","pubTimestamp":1776416700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong – Xuanzhu Biopharmaceutical Co., Ltd. announced that the Hong Kong Stock Exchange has approved the listing and dealing of 357.25 million H shares converted from unlisted shares under its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02575":"轩竹生物-B"},"translate_title":"轩竹生物制药获港交所批准3.5725万股H股全流通","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"Hong Kong – Xuanzhu Biopharmaceutical Co., Ltd. announced that the Hong Kong Stock Exchange has approved the listing and dealing of 357.25 million H shares converted from unlisted shares under its H-share Full Circulation plan.\nThe conversion involves six participating shareholders, collectively holding 68.97% of the company’s issued share capital as of 17 April 2026. Key participants include Xuanzhu (HK) Biopharmaceutical (215.29 million shares, 41.57% post-conversion) and Sihuan Pharmaceutical Holdings Group (39.16 million shares, 7.56%). Upon completion, Xuanzhu’s entire issued share capital—517.95 million shares—will be tradable as H shares on the HKEX, eliminating the previous 68.97% block of unlisted shares.\nThe company will complete the required conversion and trading procedures and will update the market on further progress. Investors are advised to exercise caution when dealing in Xuanzhu Biopharmaceutical shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124608444","isCrawlerRequest":true}